AD
ADCT.US ADC Therapeutics SA
- Market cap
- USD 198M
- P/E
- -
- P/B
- 3.42x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ADCT.US undervalued?
Graham numberThe Graham number of ADC Therapeutics SA cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ADC Therapeutics SA fundamental analysis
No fundamental analysis for ADC Therapeutics SA yet.
ADC Therapeutics SA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ADC Therapeutics SA
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or …
Full company profileADC Therapeutics SA financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ADC Therapeutics SA annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 1.80M | 1.14M | 2.34M | 0.00 | 33.9M | 210M | 69.6M | 70.8M | 81.4M | 81.3M |
| Gross Profit | -83.7M | -117M | 2.34M | -142M | 32.5M | 207M | 67.0M | 64.9M | 73.7M | 70.7M |
| Operating Income | -91.7M | -126M | -119M | -219M | -262M | -123M | -166M | -131M | -108M | -86.7M |
| EBITDA | -91.3M | -122M | -114M | -217M | -231M | -108M | -146M | -103M | -89.3M | -104M |
| Net Income | -89.9M | -123M | -116M | -246M | -230M | -157M | -240M | -158M | -143M | -99.8M |
| EPS | -1.53 | -2.29 | -1.74 | -3.77 | -3.00 | -2.01 | -2.94 | -1.62 | -1.12 | -0.64 |
| Balance Sheet | ||||||||||
| Total Assets | 272M | 151M | 138M | 514M | 618M | 491M | 355M | 322M | 323M | 256M |
| Total Liabilities | 22.8M | 24.3M | 26.5M | 178M | 452M | 411M | 503M | 525M | 509M | 505M |
| Shareholders' Equity | 249M | 126M | 111M | 336M | 166M | 79.5M | -148M | -203M | -186M | -249M |
| Cash & Short-term Investments | 263M | 139M | 116M | 439M | 467M | 326M | 279M | 251M | 261M | 189M |
| Total Debt | - | - | 5.03M | 115M | 140M | 130M | 124M | 123M | 439M | 420M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -74.9M | -121M | -122M | -169M | -233M | -137M | -119M | -124M | -141M | -92.5M |
| Capital Expenditure | 3.16M | 2.47M | 2.15M | 2.81M | 6.38M | 577K | 3.22M | 867K | 264K | 43.0K |
| Free Cash Flow | -78.1M | -124M | -124M | -172M | -240M | -137M | -122M | -125M | -141M | -92.6M |
| Ratios | ||||||||||
| ROE | -36.1% | -97.5% | -104.8% | -73.4% | -138.5% | -197.8% | - | - | - | - |
| ROA | -33.0% | -81.8% | -84.6% | -47.9% | -37.2% | -32.0% | -67.7% | -49.0% | -44.1% | -39.0% |
| Net Profit Margin | -4,984.0% | -10,797.9% | -4,977.9% | - | -678.2% | -74.9% | -345.1% | -222.8% | -175.3% | -122.7% |
| Debt to Equity | - | - | 0.05x | 0.34x | 0.84x | 1.63x | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
ADC Therapeutics SA dividends
ADC Therapeutics SA has not paid dividends in the last 9 fiscal years.
Who owns ADC Therapeutics SA
- Insiders 13.09%
- Institutions 69.52%
- Public & others 17.39%
- Shares outstanding 141M
- Free float 89.9M
Top funds holding ADCT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Russell 2000 ETF | 2.68M | 2.10% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 1.18M | 0.93% | +2.55% | Aug 2026 |
| iShares Russell 2000 Value ETF | 854K | 0.67% | 0.00% | Oct 2026 |
| iShares Biotechnology ETF | 738K | 0.58% | -0.19% | Oct 2026 |
| Vanguard Russell 2000 ETF | 620K | 0.49% | +0.63% | Sep 2026 |
| International Biotechnology Ord | 419K | 0.33% | 0.00% | Jul 2026 |
| Vanguard VIF Small Co Gr | 349K | 0.27% | +97.25% | Sep 2026 |
| iShares Micro-Cap ETF | 327K | 0.26% | 0.00% | Oct 2026 |
| Schwab Small Cap Index | 259K | 0.20% | 0.00% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 205K | 0.16% | -0.38% | Oct 2026 |
| iShares Healthcare Innov ETF USD Acc | 186K | 0.15% | 0.00% | Oct 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 173K | 0.14% | 0.00% | Sep 2026 |
| Nuveen Small Cap Blend Idx R6 | 153K | 0.12% | 0.00% | Aug 2026 |
| Stt Strt SPDR® Russell2000 US SmCapETF | 141K | 0.11% | -6.50% | Sep 2026 |
| Bridge Builder Small Cap Fund | 127K | 0.10% | 0.00% | Oct 2026 |
| Fidelity Small Cap Value Index | 125K | 0.10% | +7.55% | Aug 2026 |
| Fidelity VIP Disciplined Small Cap Init | 124K | 0.10% | 0.00% | Aug 2026 |
| EQ/2000 Managed Volatility IB | 104K | 0.08% | 0.00% | Sep 2026 |
| State Street® SPDR® S&P® Intl Sm Cp ETF | 94.8K | 0.07% | 0.00% | Oct 2026 |
| iShares Ageing Population ETF USD Acc | 89.7K | 0.07% | 0.00% | Oct 2026 |
Top institutions holding ADCT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Nantahala Capital Management, LLC | 24.7M | 19.31% | +340.42% | Jun 2026 |
| Redmile Group, LLC | 11.5M | 9.03% | -25.49% | Jun 2026 |
| TCG Crossover Management, LLC | 11.4M | 8.92% | 0.00% | Jun 2026 |
| Prosight Management, LP | 7.82M | 6.13% | -5.73% | Jun 2026 |
| BlackRock Inc | 7.02M | 5.50% | +12.31% | Jun 2026 |
| Point72 Asset Management, L.P. | 3.65M | 2.86% | +7.89% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 3.05M | 2.39% | -19.97% | Jun 2026 |
| Millennium Management LLC | 2.90M | 2.27% | -7.04% | Jun 2026 |
| Citadel Advisors Llc | 2.05M | 1.61% | +413.69% | Jun 2026 |
| The Goldman Sachs Group Inc | 1.91M | 1.50% | +15.81% | Jun 2026 |
| State Street Corp | 1.69M | 1.32% | +7.61% | Jun 2026 |
| Geode Capital Management, LLC | 1.45M | 1.13% | +20.09% | Jun 2026 |
| Bank of America Corp | 1.29M | 1.01% | -2.78% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 897K | 0.70% | -13.18% | Jun 2026 |
| Two Sigma Investments LLC | 773K | 0.61% | +15.78% | Jun 2026 |
| Blue Owl Capital Holdings LP | 734K | 0.57% | 0.00% | Jun 2026 |
| D. E. Shaw & Co LP | 719K | 0.56% | +195.80% | Jun 2026 |
| Opaleye Management Inc | 700K | 0.55% | 0.00% | Jun 2026 |
| AQR Capital Management LLC | 658K | 0.52% | +176.95% | Jun 2026 |
| BNP Paribas Arbitrage, SA | 653K | 0.51% | -24.13% | Jun 2026 |
ADC Therapeutics SA company profile
- Company name
- ADC Therapeutics SA
- Ticker
- ADCT.US
- ISIN
- CH0499880968
- Exchange
- USA Stocks
- Listed since
- Mar 16, 1979
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 188
- Fiscal year end
- December
- Address
- BiopOle, Epalinges, Switzerland, 1066
- Phone
- 41 21 653 02 00
- Website
- adctherapeutics.com
About ADC Therapeutics SA
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
ADC Therapeutics SA management
10- Dr. Ameet Mallik M.B.A., M.S.CEO & Director · born 1973
- Mr. Jose I. Carmona M.B.A.Chief Financial Officer · born 1972
- Dr. Mohamed Zaki M.D., Ph.D.Chief Medical Officer · born 1965
- Ms. Lisa Michelle KalleboCorporate Controller & Chief Accounting Officer
- Dr. David S. Ege Ph.D.Chief Technical Officer · born 1974
- Ms. Nicole RileyHead of Investor Relations & Corporate Communications
- Mr. Peter J. Graham Esq.Secretary and Chief Legal & Compliance Officer · born 1967
- Ms. Kimberly PopeSenior VP & Chief People Officer · born 1967
- Ms. Kristen Harrington-SmithChief Commercial Officer · born 1973
- Ms. Marcy GrahamInvestor Relations Officer · born 1967